PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

PureTech Health: Results of Annual General Meeting

Wed, 10 Jun 2026 13:14:00 -0400

BOSTON--(BUSINESS WIRE)-- The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.

Resolutions

For

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.

The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers